Oshadi R

Drug Profile

Oshadi R

Alternative Names: RNase in Oshadi carrier

Latest Information Update: 16 Jul 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Oshadi Drug Administration
  • Class Antineoplastics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Basal cell cancer; Non-small cell lung cancer
  • No development reported Solid tumours

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Metastatic disease) in Israel (PO, Controlled release)
  • 10 Jun 2015 Oshadi Drug Administration plans a phase II trial for Acute myeloid leukaemia and Acute lymphoblastic leukaemia (Second-line therapy or greater, Combination therapy) in Israel (NCT02462265)
  • 01 Jun 2014 Phase-II clinical trials in Non-small cell lung cancer (Second-line therapy or greater, Metastatic disease, Combination therapy) in Israel (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top